Novo Nordisk A/S (NVO)
44.38
+0.10
(+0.21%)
USD |
NYSE |
May 19, 10:09
Novo Nordisk Research and Development Expense (Quarterly) : 1.610B for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AstraZeneca PLC | 3.456B |
| GSK Plc | 2.045B |
| Johnson & Johnson | 3.495B |
| Eli Lilly & Co. | 3.51B |
| Lexicon Pharmaceuticals, Inc. | 12.65M |